Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in Kampala, Uganda

Journal of the International Association of Physicians in AIDS Care

Volumn 6, Issue 2, 2007, Pages 83-86

  Hahn, Judith A ^a   Maier, Marissa ^b   Byakika Tusiime, Jayne ^c   Oyugi, Jessica H ^d   Bangsberg, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

Author keywords

antiretroviral therapy; hepatotoxicity; HIV; Uganda

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE;

CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; PROSPECTIVE STUDY; UGANDA;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; NEVIRAPINE; PROSPECTIVE STUDIES; UGANDA;

EID: 35549000405     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109707299356     Document Type: Article

References (17)

1. Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicenter trial. Lancet. 2004 ; 364 (9428). 29-34. (Pubitemid 38968622)
2. FDA Public Health Advisory for Nevirapine (Viramune). US Food and Drug Administration. Available at: http://www.fda.gov/cder/drug/advisory/Nevirapine. htm. Accessed October 21, 2005.
3. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002 ; 35 (1). 182-189. (Pubitemid 34032559)
4. O'Brien ME, Clark RA, Besch CL, Myers L., Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003 ; 34 (4). 407-414. (Pubitemid 37444469)
5. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 ; 20 (3). 290-294. (Pubitemid 29156968)
6. Mocroft A., Youle M., Moore A., et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001 ; 15 (2). 185-194. (Pubitemid 32142293)
7. d'Arminio Monforte A., Lepri AC, Rezza G., et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000 ; 14 (5). 499-507. (Pubitemid 30209692)
8. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000 ; 283 (1). 74-80. (Pubitemid 30038386)
9. Ena J., Amador C., Benito C., Fenoll V., Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. 2003 ; 14 (11). 776-781. (Pubitemid 37372234)
10. Martin-Carbonero L., Nunez M., Gonzalez-Lahoz J., Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003 ; 4 (2). 115-120. (Pubitemid 36410915)
11. Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr. 2006 ; 43 (3). 320-323. (Pubitemid 44674012)
12. Oyugi JH, Byakika J., Ragland K., et al. Adherence predicts viral suppression while treatment interruptions predict drug resistance in HIV+ individuals purchasing fixed-dose combination generic antiretroviral therapy in Kampala, Uganda. 2006 ; Under review.
13. Babor T., Higgins-Biddle J., Saunders J., Monteiro MG The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization, Department of Mental Health and Substance Dependence; 2001.
14. Mayfield D., Mcleod G., Hall P. The CAGE Questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974 ; 131: 1121-1123.
15. Justice AC, Holmes W., Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001 ; 54 (Suppl 1). S77 - S90.
16. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet. 2004 ; 363 (9417). 1253-1263. (Pubitemid 38496486)
17. Sanne I., Mommeja-Marin H., Hinkle J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 ; 191 (6). 825-829. (Pubitemid 40349795)